We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Angle Plc | AGL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 4.00 | 29.09% | 17.75 | 16:29:58 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.25 | 15.25 | 18.25 | 17.75 | 13.75 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 03/5/2024 12:46 by mrkeysersoze Looking at the share price since AN's interview was released an hour or so ago, it seems some investors like it....Mr K. |
Posted at 03/5/2024 12:42 by adw198 Careful ohwhatfun the investors here don’t like people actually a company’s current financial performance and forecasts :)Blind faith in spades here |
Posted at 03/5/2024 12:09 by boris cobaka Seems a bit tight!Surely not with myriad investors dumping to buy back lower wtf! |
Posted at 01/5/2024 09:36 by ohwhatfun BagPerhaps it’s because we have seen so many private investors misled by companies and pump crews with ignorance of major factors which can affect investments. AGL hit 37p in the day during January over 100% up, which attracted the pump and dump dross. The recent news looked good, the tech is good. Time to buy??? No absolutely not to a sober head. Who new would buy when the chance of a high dilution discounted raise is on the cards. We can’t predict unknown potential good news events, those are gambling good luck events. AZ news came and so did the pump crew but the Jan previous spike event didn’t happen. What we do know is the cash burn rate, talk of later than expected progress, aka forecasts missed, with £6.6m (triple 2023) revenue forecast for 2024. But the big point is cash needed. Last 3 raises £18m and £20m twice. Depending if they are hitting sales forecasts, the money runs out somewhere between end of year and Q2 2025. Year end results due now (going by previous years) then the matter of fund raising will kick in. Unless of course all is on track, no deviation news needed (forecast missed) and raise chat is already in play. Time will tell. And to the other poster, what has shorting got to do with anything, shorter target crazy valuation retail flooded shares where raises are needed, nailed on good returns there. I don’t consider AGL to be in that situation, It was not too long ago, but has fallen for some time. It won’t be too long before the cash situation is resolved. A number of previous backers are well out of pocket they will want special treatment. Until funding is sorted many won’t buy , regular holders will have sold some or all, waiting for the raise, to get back in. |
Posted at 30/4/2024 08:33 by bones699 Clearly cr@p financial results expected and more 'jam' tommorrow from Newland with a subtle hint that 'strategic' options include a cash raise but at what price to 'mug' sorry entice investors I'm going 8p! |
Posted at 29/4/2024 07:39 by ohwhatfun GspannerThe news caught attention, some will have had AGL sat in the background waiting for interest/traction, lurking rather than avid followers. Check out the share price performance and confusing lack of interest in recent years in their tech. AZ prompt a look, time to buy? The deeper look shows last raise £20m in 2022 at 80p. Various forecasts of a cash runway, H2 2024 to Q1 25 to into Q2 25. The last business update included, slower than expected. The small cap market has been decimated, share prices obliterated, a mass of examples of angry investors where large discounts have been in play and share price collapses immediately before fund raises. Posts of yeah buy now big deal, but sensible, risk averse investors look at the full picture. AGL appear to have left it later in the day to raise funds than usual, perhaps hoping for a higher share price on the back of news. The market knows they need money, the market is highly risk averse, so if AGL go to market for funding, the market will drop the share price and discount from there. If 15p is to be the share price pre fund raise game, then a 10p raise would be generous. It’s just sober market opinions, unaffected by holding (loss or profits). Typically those shouting the loudest pumping, are looking for a quick exit, knowing the loitering cash issue will impact the share price. Chances of avoiding dilution are unknown, it’s a coin flip. How many avoid it is the best guide pretty much all have had major dilution with some failing to attract funding at all. That’s how some see it, it’s opinions based on the reality of the market. The chance of normal market behaviour on a fund raise for AGL, is high. |
Posted at 27/4/2024 09:33 by ohwhatfun HtThe market/city doesn’t care, max discount for max gains, what AGL do is not of interest to market makers. In other news Some are lurking investors not salivating shorters. AGL took its time but traction finally appearing, the historic cash burn does seem high though. It will be good to get the raise out of the way, bound to be some angry PIs if the market does to AGL (likely) what it has done to near all other small caps in recent times. |
Posted at 22/1/2024 22:07 by bones699 The Edison Theranos machine comparison is a good comparison to Parsortix why is the CEO at the Investor Meet ramping a testing machine that is far away from being fully approved by the FDA and is reliant on third party machines..You simply can't use Parsortix to test any cancer other than breast cancers so why when asked by an Investor he states you can use it if you have a 'handle on it to test for other cancers so long as you are an accredited lab'...Nonsense the correct answer is 'No you can't use Parsortix to test cancers other than for testing breast cancer'.. So why the waffle when answering the Investors very pertinent question! And why did that women monitoring questions as soon as he asked about FDA approval try and forcefully seize the mick out of his hand...Anything you would like to add Newland? |
Posted at 10/1/2024 23:26 by 5oletrader (Addition to my last post) Institutional Investors often have SPECIFIC PREFERENCEs that they would like to convey to the COMPANIES in their portfolio. Investors have various mechanisms for INFLUENCING COMPANIES.- Global Frontier Investments LLC - Holds AGL & Accenture (ACN). ACN works closely with ROCHE. Remember the word - INFLUENCE.-I note this guy Maxim Lewinz is employed by ACN - involved in their Life Science Strategy. He published a piece on 8th JAN24 titled: WILL 2024 BE A LEAP YEAR FOR LIQUID BIOPSY?-"LIQUID BIOPSY going MAINSTREAM may have several IMPLICATIONS that BIOPHARMA companies are already STARTING to PREPARE for." This includes: To Consider PARTNERING with select LIQUID BIOPSY COMPANIES to build competitive advantage, e.g., in developing targeted oncology products.-FUNDs from FINANCIAL INVESTORs are pouring into companies like Guardant Health, Natera and ILLUMINA, reflecting a BULLISH SENTIMENT around the LIQUID BIOPSY MARKET. This is fueled by several factors: Increasing SUPPORT from REGULATORS, most importantly demonstrated by FDA's 2022 guidance document "Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development" INCREASING number of oncology TRIALS using LIQUID BIOPSY Upcoming LAUNCH of multiple KEY PRODUCTs-Article here:https://www.lin |
Posted at 26/11/2023 17:51 by 5oletrader One for the diary? Plugging AGL to US investors.I note this coming week on Thursday 30th Nov at 17:00GMT - AGL will be presenting at the Small Cap Growth Virtual Investor Conference.https://w |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
